Hemp Processing

High-Volume Cannabinoid Isolation for Hemp Processors

Pharmaceutical-grade CBD, CBG, and minor cannabinoid isolate production at commercial scale.

The hemp-derived cannabinoid market is undergoing a fundamental shift. As the FDA moves toward a regulatory framework for hemp-derived CBD and other cannabinoids in food, dietary supplements, and pharmaceutical applications, the quality and documentation standards required to access premium markets are rising sharply.

Prodigy systems give hemp processors the pharmaceutical-grade infrastructure needed to supply the highest-value market segments — pharmaceutical APIs, dietary supplement manufacturers, and international markets requiring CE/PED and EU GMP documentation. The MPS 30 Multi-Processing System is specifically designed for the post-processing workflow that produces ~99%+ pure cannabis isolate (e.g., THCA) from hemp-derived crude extract.

Why Move Beyond Commodity CBD? The commodity CBD market is crowded and margin-compressed. Processors who invest in pharmaceutical-grade infrastructure can access higher-value market segments: pharmaceutical API supply chains, dietary supplement manufacturers requiring cGMP documentation, and international markets with CE/PED and EU GMP requirements. The result is higher margins, longer-term customer relationships, and a defensible market position built on quality and documentation rather than price alone.

Note: Prodigy equipment and documentation support these regulatory pathways. Market access ultimately depends on the customer's facility, quality management system, procedures, personnel, and regulatory approvals.